BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 223] [Article Influence: 20.6] [Reference Citation Analysis]
Number Citing Articles
1 Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta. 2011;1812:1557-1566. [PMID: 21840395 DOI: 10.1016/j.bbadis.2011.07.017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
2 Orlacchio A, Bolacchi F, Antonicoli M, Coco I, Costanzo E, Tosti D, Francioso S, Angelico M, Simonetti G. Liver elasticity in NASH patients evaluated with real-time elastography (RTE). Ultrasound Med Biol. 2012;38:537-544. [PMID: 22341049 DOI: 10.1016/j.ultrasmedbio.2011.12.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
3 Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis 2015;11:888-94. [PMID: 25240529 DOI: 10.1016/j.soard.2014.07.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Wang Z, Xu M, Hu Z, Hultström M, Lai E. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol 2014;26:1015-21. [PMID: 25003744 DOI: 10.1097/MEG.0000000000000151] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
5 Rusli F, Lute C, Boekschoten MV, van Dijk M, van Norren K, Menke AL, Müller M, Steegenga WT. Intermittent calorie restriction largely counteracts the adverse health effects of a moderate-fat diet in aging C57BL/6J mice. Mol Nutr Food Res 2017;61. [PMID: 27995741 DOI: 10.1002/mnfr.201600677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 16.6] [Reference Citation Analysis]
7 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
8 Arrese M. Liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol 2010;6:660-1. [DOI: 10.1038/nrendo.2010.173] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
9 Li MR, Zhang SH, Chao K, Liao XH, Yao JY, Chen MH, Zhong BH. Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World J Gastroenterol 2014; 20(38): 14010-14017 [PMID: 25320541 DOI: 10.3748/wjg.v20.i38.14010] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
10 Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y, Lu J, Wang W, Bi Y, Ning G. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore) 2015;94:e1682. [PMID: 26448014 DOI: 10.1097/MD.0000000000001682] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 11.8] [Reference Citation Analysis]
11 Parry SA, Hodson L. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review. Adv Ther 2020;37:1381-406. [PMID: 32146704 DOI: 10.1007/s12325-020-01281-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
12 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 28.9] [Reference Citation Analysis]
13 Park CY, Choi E, Yang HJ, Ho SH, Park SJ, Park KM, Kim SH. Efficacy of Artemisia annua L. extract for recovery of acute liver failure. Food Sci Nutr 2020;8:3738-49. [PMID: 32724636 DOI: 10.1002/fsn3.1662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
16 Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66:2055-2065. [PMID: 28777879 DOI: 10.1002/hep.29420] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 24.5] [Reference Citation Analysis]
17 Oseini AM, Cole BK, Issa D, Feaver RE, Sanyal AJ. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatol Int 2018;12:6-16. [PMID: 29299759 DOI: 10.1007/s12072-017-9838-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
18 Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis. 2012;13:153-160. [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
19 Schultz Moreira AR, Rüschenbaum S, Schefczyk S, Hendgen-Cotta U, Rassaf T, Broering R, Hardtke-Wolenski M, Buitrago-Molina LE. 9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes. Int J Mol Sci 2020;21:E8279. [PMID: 33167328 DOI: 10.3390/ijms21218279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
20 Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. [PMID: 20531177 DOI: 10.1097/MCO.0b013e32833aae84] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cabrera D, Cabello-Verrugio C, Solís N, San Martín D, Cofré C, Pizarro M, Arab JP, Abrigo J, Campos F, Irigoyen B, Carrasco-Avino G, Bezares K, Riquelme V, Riquelme A, Arrese M, Barrera F. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. Int J Mol Sci 2018;19:E1339. [PMID: 29724029 DOI: 10.3390/ijms19051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
22 Jung TW, Kyung EJ, Kim H, Shin YK, Lee SH, Park ES, Hacımüftüoğlu A, Abd El-aty AM, Jeong JH. Protectin DX Ameliorates Hepatic Steatosis by Suppression of Endoplasmic Reticulum Stress via AMPK-Induced ORP150 Expression. J Pharmacol Exp Ther 2018;365:485-93. [DOI: 10.1124/jpet.117.246686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
23 Anstee Q, Day C. A lipid to treat non-alcoholic fatty liver disease – The dawn of ‘lipo-rehabilitation’? Journal of Hepatology 2012;56:987-9. [DOI: 10.1016/j.jhep.2011.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Wang Z, Xu M, Peng J, Jiang L, Hu Z, Wang H, Zhou S, Zhou R, Hultström M, Lai EY. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Exp Gerontol. 2013;48:705-709. [PMID: 23721951 DOI: 10.1016/j.exger.2013.05.059] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
25 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 34.3] [Reference Citation Analysis]
26 Perng W, Francis EC, Smith HA, Carey J, Wang D, Kechris KM, Dabelea D. Sex-Specific Metabolite Biomarkers of NAFLD in Youth: A Prospective Study in the EPOCH Cohort. J Clin Endocrinol Metab 2020;105:dgaa467. [PMID: 32687159 DOI: 10.1210/clinem/dgaa467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
28 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014.Epub] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Pinidiyapathirage MJ, Dassanayake AS, Rajindrajith S, Kalubowila U, Kato N, Wickremasinghe AR, de Silva HJ. Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. BMC Res Notes. 2011;4:513. [PMID: 22115060 DOI: 10.1186/1756-0500-4-513] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
30 Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, Tripodi A, Trotter JF, Valla D, Porte RJ. Hemostasis and thrombosis in patients with liver disease: The ups and downs. Journal of Hepatology 2010;53:362-71. [DOI: 10.1016/j.jhep.2010.01.042] [Cited by in Crossref: 242] [Cited by in F6Publishing: 188] [Article Influence: 22.0] [Reference Citation Analysis]
31 Wang Y, van der Tuin S, Tjeerdema N, van Dam AD, Rensen SS, Hendrikx T, Berbée JF, Atanasovska B, Fu J, Hoekstra M, Bekkering S, Riksen NP, Buurman WA, Greve JW, Hofker MH, Shiri-sverdlov R, Meijer OC, Smit JW, Havekes LM, van Dijk KW, Rensen PC. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells: HEPATOLOGY, Vol. XX, No. X, 2015. Hepatology 2015;62:1710-22. [DOI: 10.1002/hep.27985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
32 Derakhshandeh-Rishehri SM, Heidari-Beni M, Eftekhari MH. THE EFFECTS OF REALSIL (SILYBIN-PHOSPHOLIPID-VITAMIN E COMPLEX) ON LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) OR NON-ALCOHOLIC STEATO-HEPATITIS (NASH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS. Acta Endocrinol (Buchar) 2020;16:223-31. [PMID: 33029240 DOI: 10.4183/aeb.2020.223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Popov VB, Jornayvaz FR, Akgul EO, Kanda S, Jurczak MJ, Zhang D, Abudukadier A, Majumdar SK, Guigni B, Petersen KF. Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. FASEB J. 2016;30:1207-1217. [PMID: 26644352 DOI: 10.1096/fj.15-271999] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yen FS, Yang YC, Hwu CM, Wei JC, Huang YH, Hou MC, Hsu CC. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. Liver Int. 2020;40:1089-1097. [PMID: 31960563 DOI: 10.1111/liv.14385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Argo CK, Stine JG, Henry ZH, Lackner C, Patrie JT, Weltman AL, Caldwell SH. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2018;48:290-9. [PMID: 29797529 DOI: 10.1111/apt.14803] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T, Sadamori H, Fujiwara T. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J Hepatol 2013; 5(4): 189-195 [PMID: 23671723 DOI: 10.4254/wjh.v5.i4.189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
37 Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci. 2017;13:852-867. [PMID: 28808418 DOI: 10.7150/ijbs.19370] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 26.3] [Reference Citation Analysis]
38 Li J, Cordero P, Nguyen V, Oben JA. The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Integr Med Insights 2016;11:19-25. [PMID: 27147819 DOI: 10.4137/IMI.S31451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
39 Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, Li H, Zhang X. Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 2013;12:165. [PMID: 24188280 DOI: 10.1186/1476-511x-12-165] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 5.9] [Reference Citation Analysis]
40 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1795] [Article Influence: 494.5] [Reference Citation Analysis]
41 Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-16. [PMID: 21688282 DOI: 10.1002/hep.24491] [Cited by in Crossref: 305] [Cited by in F6Publishing: 281] [Article Influence: 30.5] [Reference Citation Analysis]
42 Xiao J, Fai So K, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J Tradit Complement Med 2013;3:88-94. [PMID: 24716162 DOI: 10.4103/2225-4110.110411] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 7.9] [Reference Citation Analysis]
43 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
44 Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98. [PMID: 20738844 DOI: 10.1186/1471-230x-10-98] [Cited by in Crossref: 123] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
45 Ozturk Y, Soylu OB. Fatty liver in childhood. World J Hepatol 2014; 6(1): 33-40 [PMID: 24653792 DOI: 10.4254/wjh.v6.i1.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
46 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
47 Jung TW, Hong HC, Hwang H, Yoo HJ, Baik SH, Choi KM. C1q/TNF-Related Protein 9 (CTRP9) attenuates hepatic steatosis via the autophagy-mediated inhibition of endoplasmic reticulum stress. Molecular and Cellular Endocrinology 2015;417:131-40. [DOI: 10.1016/j.mce.2015.09.027] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
48 Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013;52 Suppl 1:E139-E147. [PMID: 23776098 DOI: 10.1002/mc.22057] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
49 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
50 Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, Fragopoulou E, Zafiropoulou R, Manios Y, Papatheodoridis G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33:678-683. [PMID: 24064253 DOI: 10.1016/j.clnu.2013.08.014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 13.8] [Reference Citation Analysis]
51 Gao E, Hercun J, Heller T, Vilarinho S. Undiagnosed liver diseases. Transl Gastroenterol Hepatol 2021;6:28. [PMID: 33824932 DOI: 10.21037/tgh.2020.04.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Djiambou-Nganjeu H. Hepatic Encephalopathy in Patients in Lviv (Ukraine). J Transl Int Med. 2018;6:146-151. [PMID: 30425951 DOI: 10.2478/jtim-2018-0021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Vatner DF, Snikeris J, Popov V, Perry RJ, Rahimi Y, Samuel VT. 3,5 Diiodo-L-Thyronine (T2) Does Not Prevent Hepatic Steatosis or Insulin Resistance in Fat-Fed Sprague Dawley Rats. PLoS One 2015;10:e0140837. [PMID: 26485433 DOI: 10.1371/journal.pone.0140837] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
54 Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N, Rao S, Yao X, Wu W, Pan B, Bian H, Gao X. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 2020;36:e3292. [PMID: 31955491 DOI: 10.1002/dmrr.3292] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
55 Seo SW, Gottesman RF, Clark JM, Hernaez R, Chang Y, Kim C, Ha KH, Guallar E, Lazo M. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology 2016;86:1136-42. [PMID: 26911638 DOI: 10.1212/WNL.0000000000002498] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 11.4] [Reference Citation Analysis]
56 Motamed N, Faraji AH, Khonsari MR, Maadi M, Tameshkel FS, Keyvani H, Ajdarkosh H, Karbalaie Niya MH, Rezaie N, Zamani F. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. Clin Nutr 2020;39:468-74. [PMID: 30922791 DOI: 10.1016/j.clnu.2019.02.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
57 Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2012;23:365-371. [PMID: 22609053 DOI: 10.1016/j.tem.2012.04.005] [Cited by in Crossref: 182] [Cited by in F6Publishing: 178] [Article Influence: 20.2] [Reference Citation Analysis]
58 Moran MW, Ramirez EP, Zook JD, Saarinen AM, Baravati B, Goode MR, Laloudakis V, Kaschner EK, Olson TL, Craciunescu FM, Hansen DT, Liu J, Fromme P. Biophysical characterization and a roadmap towards the NMR solution structure of G0S2, a key enzyme in non-alcoholic fatty liver disease. PLoS One 2021;16:e0249164. [PMID: 34260600 DOI: 10.1371/journal.pone.0249164] [Reference Citation Analysis]
59 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
60 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:189-200. [DOI: 10.1586/egh.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
61 Chen K, Lin J, Yao H, Hsu A, Tai Y, Chen J, Hsieh M, Shen T, Hsu R, Wu H, Wang GH, Ho B, Chen Y. Arctigenin protects against steatosis in WRL68 hepatocytes through activation of phosphoinositide 3-kinase/protein kinase B and AMP-activated protein kinase pathways. Nutrition Research 2018;52:87-97. [DOI: 10.1016/j.nutres.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Theilade S, Christensen MB, Vilsbøll T, Knop FK. An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes Obes Metab 2021;23 Suppl 1:17-35. [PMID: 33621414 DOI: 10.1111/dom.14270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 McFarlane M, Hammond C, Roper T, Mukarati J, Ford R, Burrell J, Gordon V, Burch N. Comparing assessment tools for detecting undernutrition in patients with liver cirrhosis. Clin Nutr ESPEN. 2018;23:156-161. [PMID: 29460792 DOI: 10.1016/j.clnesp.2017.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
64 Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60:1920-1928. [PMID: 25103310 DOI: 10.1002/hep.27362] [Cited by in Crossref: 266] [Cited by in F6Publishing: 243] [Article Influence: 38.0] [Reference Citation Analysis]
65 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 53.7] [Reference Citation Analysis]
66 Li L, Fu J, Sun J, Liu D, Chen C, Wang H, Hou Y, Xu Y, Pi J. Is Nrf2-ARE a potential target in NAFLD mitigation? Current Opinion in Toxicology 2019;13:35-44. [DOI: 10.1016/j.cotox.2018.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Berzigotti A, Abraldes JG. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol. 2013;36:527-533. [PMID: 23731977 DOI: 10.1016/j.gastrohep.2013.03.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
68 Reichman TW, Therapondos G, Serrano MS, Seal J, Evers-Meltzer R, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D, Loss GE. “Weighing the risk”: Obesity and outcomes following liver transplantation. World J Hepatol 2015; 7(11): 1484-1493 [PMID: 26085908 DOI: 10.4254/wjh.v7.i11.1484] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
69 Chou M, Chang R, Hung Y, Chen Y, Chiu C. Antrodia camphorata ameliorates high-fat-diet induced hepatic steatosis via improving lipid metabolism and antioxidative status. Journal of Functional Foods 2013;5:1317-25. [DOI: 10.1016/j.jff.2013.04.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
70 Kietzmann T. Liver Zonation in Health and Disease: Hypoxia and Hypoxia-Inducible Transcription Factors as Concert Masters. Int J Mol Sci 2019;20:E2347. [PMID: 31083568 DOI: 10.3390/ijms20092347] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
71 Xu L, Nagata N, Ota T. Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. Int J Mol Sci 2019;20:E5920. [PMID: 31775341 DOI: 10.3390/ijms20235920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
72 Vauzour D, Rodriguez-ramiro I, Rushbrook S, Ipharraguerre IR, Bevan D, Davies S, Tejera N, Mena P, de Pascual-teresa S, Del Rio D, Gavrilovic J, Minihane AM. n-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:69-78. [DOI: 10.1016/j.bbadis.2017.10.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
73 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
74 Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis. World J Gastroenterol 2014; 20(17): 4987-4993 [PMID: 24803810 DOI: 10.3748/wjg.v20.i17.4987] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
75 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
76 Bruno S, Herrera Sanchez MB, Pasquino C, Tapparo M, Cedrino M, Tetta C, Camussi G. Human Liver-Derived Stem Cells Improve Fibrosis and Inflammation Associated with Nonalcoholic Steatohepatitis. Stem Cells Int 2019;2019:6351091. [PMID: 31281379 DOI: 10.1155/2019/6351091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
77 Bae JS, Lee DH, Lee JY, Kim H, Yu SJ, Lee JH, Cho EJ, Lee YB, Han JK, Choi BI. Assessment of hepatic steatosis by using attenuation imaging: a quantitative, easy-to-perform ultrasound technique. Eur Radiol. 2019;. [PMID: 31175413 DOI: 10.1007/s00330-019-06272-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
78 Mahmoodzadeh Y, Mazani M, Rezagholizadeh L. Hepatoprotective effect of methanolic Tanacetum parthenium extract on CCl4-induced liver damage in rats. Toxicol Rep 2017;4:455-62. [PMID: 28959674 DOI: 10.1016/j.toxrep.2017.08.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
79 Sharma S, Barrett F, Adamson J, Todd A, Megson IL, Zentler-Munro PL, MacRury SM. Diabetic fatty liver disease is associated with specific changes in blood-borne markers. Diabetes Metab Res Rev 2012;28:343-8. [PMID: 22576780 DOI: 10.1002/dmrr.2269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 470] [Article Influence: 63.3] [Reference Citation Analysis]
81 Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc. 2012;111:527-535. [PMID: 23089687 DOI: 10.1016/j.jfma.2012.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
82 Go KL, Lee S, Behrns KE, Kim J. Mitochondrial Damage and Mitophagy in Ischemia/Reperfusion-Induced Liver Injury. In: Ding W, Yin X, editors. Molecules, Systems and Signaling in Liver Injury. Cham: Springer International Publishing; 2017. pp. 183-219. [DOI: 10.1007/978-3-319-58106-4_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 12.4] [Reference Citation Analysis]
84 Jirapinyo P, Cenaj O, Ryou M, Thompson CC. Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis? ACG Case Rep J 2019;6:e00142. [PMID: 31620539 DOI: 10.14309/crj.0000000000000142] [Reference Citation Analysis]
85 Cao CY, Li YY, Zhou YJ, Nie YQ, Wan YJ. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med 2012;227:253-62. [PMID: 22820754 DOI: 10.1620/tjem.227.253] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
86 Abdel-Razik A, Mousa N, Shabana W, Yassen AH, Abdelsalam M, Wahba MM, Helmy EM, Tawfik AM, Zalata K, Hasan AS, Elhelaly R, Elzehery R, Fathy AA, El-Wakeel N, Eldars W. De novo Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study. Front Med (Lausanne) 2021;8:650818. [PMID: 33996858 DOI: 10.3389/fmed.2021.650818] [Reference Citation Analysis]
87 O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, Asiki G, Seeley J, Matthews PC, Newton R. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open 2020;10:e032890. [PMID: 32234740 DOI: 10.1136/bmjopen-2019-032890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141-145. [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
89 Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 2015;21:1016-1021. [PMID: 25845711 DOI: 10.1002/lt.24134] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
90 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
91 Li X, Liu L, Li R, Wu A, Lu J, Wu Q, Jia J, Zhao M, Song H. Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice. J Biol Chem 2018;293:5160-71. [PMID: 29475944 DOI: 10.1074/jbc.RA117.001474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
92 Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011;44:652-9. [DOI: 10.1590/s0100-879x2011007500083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
93 Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, Rustgi V. Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2021;55:433-8. [PMID: 32740097 DOI: 10.1097/MCG.0000000000001389] [Reference Citation Analysis]
94 Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013;5:654-665. [PMID: 24210820 DOI: 10.1016/j.celrep.2013.10.007] [Cited by in Crossref: 166] [Cited by in F6Publishing: 145] [Article Influence: 20.8] [Reference Citation Analysis]
95 Williams R, Horton R. Liver disease in the UK: a Lancet Commission. Lancet 2013;382:1537-8. [PMID: 24209811 DOI: 10.1016/S0140-6736(13)62152-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
96 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
97 Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 2013;6:77-84. [PMID: 23935723 DOI: 10.3892/etm.2013.1090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
98 Calza L, Colangeli V, Borderi M, Coladonato S, Tazza B, Fornaro G, Badia L, Guardigni V, Verucchi G, Viale P. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. Infect Dis (Lond) 2019;51:593-601. [PMID: 31219362 DOI: 10.1080/23744235.2019.1629008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
99 Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654. [PMID: 23686698 DOI: 10.1002/hep.26465] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 12.9] [Reference Citation Analysis]
100 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 800] [Article Influence: 107.6] [Reference Citation Analysis]
101 Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J 2010;16:125-31. [PMID: 20404609 DOI: 10.1097/PPO.0b013e3181d823c8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
102 Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47:215-225. [PMID: 22310735 DOI: 10.1007/s00535-012-0527-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 11.0] [Reference Citation Analysis]
103 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 57.3] [Reference Citation Analysis]
104 Bosoi CR, Vandal M, Tournissac M, Leclerc M, Fanet H, Mitchell PL, Verreault M, Trottier J, Virgili J, Tremblay C, Lippman HR, Bajaj JS, Barbier O, Marette A, Calon F. High-Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease. Hepatol Commun 2021;5:446-60. [PMID: 33681678 DOI: 10.1002/hep4.1609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Iruzubieta P, Terán &, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol 2014; 6(12): 901-915 [PMID: 25544877 DOI: 10.4254/wjh.v6.i12.901] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
106 Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol 2017;11:759-72. [PMID: 28613087 DOI: 10.1080/17474124.2017.1342535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
107 Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim 2019;68:147-58. [PMID: 30487357 DOI: 10.1538/expanim.18-0108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
108 Kim JK, Lee KS, Lee DK, Lee SY, Chang HY, Choi J, Lee JI. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Exp Mol Med 2014;46:e127. [PMID: 25523099 DOI: 10.1038/emm.2014.90] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
109 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313-326. [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003] [Cited by in Crossref: 183] [Cited by in F6Publishing: 180] [Article Influence: 16.6] [Reference Citation Analysis]
110 Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299. [PMID: 23512725 DOI: 10.1002/oby.20426] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
111 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
112 Zhao L, Westerhoff M, Pai RK, Choi WT, Gao ZH, Hart J. Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis. Mod Pathol 2018;31:150-9. [PMID: 28862262 DOI: 10.1038/modpathol.2017.115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
113 Khaleel EF, Abdel-aleem GA, Mostafa DG. Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element-binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. Can J Physiol Pharmacol 2018;96:145-57. [DOI: 10.1139/cjpp-2017-0001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
114 Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. Food Chem Toxicol 2019;125:595-604. [PMID: 30738135 DOI: 10.1016/j.fct.2019.02.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
115 Stine JG, Northup PG. Coagulopathy Before and After Liver Transplantation: From the Hepatic to the Systemic Circulatory Systems. Clin Liver Dis 2017;21:253-74. [PMID: 28364812 DOI: 10.1016/j.cld.2016.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
116 Kim JK, Lee KS, Chang HY, Lee WK, Lee JI. Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice. J Transl Med 2014;12:186. [PMID: 24986741 DOI: 10.1186/1479-5876-12-186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
117 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155. [PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034] [Cited by in Crossref: 526] [Cited by in F6Publishing: 479] [Article Influence: 75.1] [Reference Citation Analysis]
118 Sun HY, Chen TY, Tan YC, Wang CH, Young KC. Sterol O-acyltransferase 2 chaperoned by apolipoprotein J facilitates hepatic lipid accumulation following viral and nutrient stresses. Commun Biol 2021;4:564. [PMID: 33980978 DOI: 10.1038/s42003-021-02093-2] [Reference Citation Analysis]
119 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
120 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
121 Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;  JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595. [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z] [Cited by in Crossref: 268] [Cited by in F6Publishing: 232] [Article Influence: 29.8] [Reference Citation Analysis]
122 Mazo DF, de Oliveira MG, Pereira IV, Cogliati B, Stefano JT, de Souza GF, Rabelo F, Lima FR, Ferreira Alves VA, Carrilho FJ. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Des Devel Ther. 2013;7:553-563. [PMID: 23843692 DOI: 10.2147/dddt.s43930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
123 Moradi Kelardeh B, Rahmati-Ahmadabad S, Farzanegi P, Helalizadeh M, Azarbayjani MA. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. J Bodyw Mov Ther 2020;24:154-60. [PMID: 32825982 DOI: 10.1016/j.jbmt.2020.02.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The Severity of Histologic Liver Lesions Is Independent of Body Mass Index in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:280-6. [DOI: 10.1097/mcg.0b013e31826be328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
125 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
126 Mendonsa AM, VanSaun MN, Ustione A, Piston DW, Fingleton BM, Gorden DL. Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver. Mol Cancer 2015;14:49. [PMID: 25880591 DOI: 10.1186/s12943-014-0282-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
127 Suzuki-Kemuriyama N, Matsuzaka T, Kuba M, Ohno H, Han SI, Takeuchi Y, Isaka M, Kobayashi K, Iwasaki H, Yatoh S, Suzuki H, Miyajima K, Nakae D, Yahagi N, Nakagawa Y, Sone H, Yamada N, Shimano H. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. PLoS One 2016;11:e0157580. [PMID: 27333187 DOI: 10.1371/journal.pone.0157580] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
128 Kampschulte M, Stöckl C, Langheinrich AC, Althöhn U, Bohle RM, Krombach GA, Stieger P, Churin Y, Kremer S, Dierkes C, Rath T, Roeb E, Roderfeld M. Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab Invest 2014;94:1273-82. [DOI: 10.1038/labinvest.2014.112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
129 Vendhan R, Amutha A, Anjana RM, Unnikrishnan R, Deepa M, Mohan V. Comparison of characteristics between nonobese and overweight/obese subjects with nonalcoholic fatty liver disease in a South Indian population. Diabetes Technol Ther 2014;16:48-55. [PMID: 24028151 DOI: 10.1089/dia.2013.0165] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
130 Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, Fujisawa K, Matsunaga K, Shimosegawa E, Abe K. Quantitative evaluation of hepatic integrin αvβ3 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res 2020;10:118. [PMID: 33026561 DOI: 10.1186/s13550-020-00704-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol. 2012;46:427-430. [PMID: 22469639 DOI: 10.1097/mcg.0b013e31822fb3f7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
132 Weinstein AA, de Avila L, Paik J, Golabi P, Escheik C, Gerber L, Younossi ZM. Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. Psychosomatics 2018;59:567-74. [DOI: 10.1016/j.psym.2018.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
133 Gorden A, Yang R, Yerges-Armstrong LM, Ryan KA, Speliotes E, Borecki IB, Harris TB, Chu X, Wood GC, Still CD, Shuldiner AR, Gerhard GS; GOLD Consortium. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered 2013;75:34-43. [PMID: 23594525 DOI: 10.1159/000346195] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
134 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
135 Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519-527. [PMID: 25617046 DOI: 10.1586/17474124.2015.1004312] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
136 Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int. 2013;7 Suppl 2:765-770. [PMID: 26202292 DOI: 10.1007/s12072-013-9446-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
137 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
138 Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y; Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD). Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res 2014;44:1196-207. [PMID: 24372862 DOI: 10.1111/hepr.12293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
139 Kaul A, Singla V, Baksi A, Aggarwal S, Bhambri A, Shalimar D, Yadav R. Safety and Efficacy of Bariatric Surgery in Advanced Liver Fibrosis. Obes Surg 2020;30:4359-65. [PMID: 33900587 DOI: 10.1007/s11695-020-04827-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
140 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048. [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012] [Cited by in Crossref: 901] [Cited by in F6Publishing: 855] [Article Influence: 180.2] [Reference Citation Analysis]
141 Ferreyra Solari NE, Inzaugarat ME, Baz P, De Matteo E, Lezama C, Galoppo M, Galoppo C, Cherñavsky AC. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol 2012;32:611-21. [PMID: 22228550 DOI: 10.1007/s10875-011-9635-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
142 Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 2016;29:77-89. [PMID: 27429211 DOI: 10.1016/j.coph.2016.07.005] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 20.0] [Reference Citation Analysis]
143 Nie YQ, Cao J, Zhou YJ, Liang X, Du YL, Wan YJ, Li YY. The effect of miRNA-122 in regulating fat deposition in a cell line model. J Cell Biochem. 2014;115:839-846. [PMID: 24288170 DOI: 10.1002/jcb.24725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
144 Ratziu V, Cadranel JF, Serfaty L, Denis J, Renou C, Delassalle P, Bernhardt C, Perlemuter G. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol. 2012;57:376-383. [PMID: 22521354 DOI: 10.1016/j.jhep.2012.03.019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
145 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol 2020;35:1579-89. [PMID: 31975453 DOI: 10.1111/jgh.14989] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
146 Morrill KE, Bland VL, Klimentidis YC, Hingle MD, Thomson CA, Garcia DO. Assessing Interactions between PNPLA3 and Dietary Intake on Liver Steatosis in Mexican-Origin Adults. Int J Environ Res Public Health 2021;18:7055. [PMID: 34280991 DOI: 10.3390/ijerph18137055] [Reference Citation Analysis]
147 Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C, Ernesti I, Pannitteri G, Violi F, Angelico F, Del Ben M. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol. 2017;112:1832-1839. [PMID: 29063908 DOI: 10.1038/ajg.2017.371] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
148 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76. [PMID: 23855299 DOI: 10.1111/jgh.12212] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 21.1] [Reference Citation Analysis]
149 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
150 Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. Aliment Pharmacol Ther 2020;51:1200-1. [PMID: 32424927 DOI: 10.1111/apt.15724] [Reference Citation Analysis]
151 Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011;2011:831536. [PMID: 21918648 DOI: 10.1155/2011/831536] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
152 Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl). 2016;94:613-627. [PMID: 27094811 DOI: 10.1007/s00109-016-1408-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 13.0] [Reference Citation Analysis]
153 Kuba M, Matsuzaka T, Matsumori R, Saito R, Kaga N, Taka H, Ikehata K, Okada N, Kikuchi T, Ohno H, Han SI, Takeuchi Y, Kobayashi K, Iwasaki H, Yatoh S, Suzuki H, Sone H, Yahagi N, Arakawa Y, Fujimura T, Nakagawa Y, Yamada N, Shimano H. Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model. Sci Rep 2015;5:17604. [PMID: 26619823 DOI: 10.1038/srep17604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
154 Wang L, Sun M, Cao Y, Ma L, Shen Y, Velikanova AA, Li X, Sun C, Zhao Y. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Arch Biochem Biophys 2020;695:108642. [PMID: 33098868 DOI: 10.1016/j.abb.2020.108642] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2016;65:1080-6. [PMID: 26775559 DOI: 10.1016/j.metabol.2015.11.008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 15.3] [Reference Citation Analysis]
156 Yang M, Li X, Zeng X, Ou Z, Xue M, Gao D, Liu S, Li X, Yang S. Rheum palmatum L. Attenuates High Fat Diet-Induced Hepatosteatosis by Activating AMP-Activated Protein Kinase. Am J Chin Med 2016;44:551-64. [DOI: 10.1142/s0192415x16500300] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
157 Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011;15:505-521. [PMID: 21128705 DOI: 10.1089/ars.2010.3790] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]
158 Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006. [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004] [Cited by in Crossref: 246] [Cited by in F6Publishing: 223] [Article Influence: 41.0] [Reference Citation Analysis]
159 Flores-Toro JA, Go KL, Leeuwenburgh C, Kim JS. Autophagy in the liver: cell's cannibalism and beyond. Arch Pharm Res. 2016;39:1050-1061. [PMID: 27515049 DOI: 10.1007/s12272-016-0807-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
160 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
161 Sowa JP, Heider D, Bechmann LP, Gerken G, Hoffmann D, Canbay A. Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One 2013;8:e62439. [PMID: 23638085 DOI: 10.1371/journal.pone.0062439] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
162 Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015;274:416-25. [PMID: 25247408 DOI: 10.1148/radiol.14140754] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 18.7] [Reference Citation Analysis]
163 Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011;15:485-504. [PMID: 21128703 DOI: 10.1089/ars.2010.3795] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
164 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 27.7] [Reference Citation Analysis]
165 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
166 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
167 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-48. [DOI: 10.1016/j.metabol.2015.12.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Di Minno MND, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18(41): 5839-5847 [PMID: 23139599 DOI: 10.3748/wjg.v18.i41.5839] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
169 Paquette M, Gauthier D, Chamberland A, Prat A, De Lucia Rolfe E, Rasmussen JJ, Kaduka L, Seidah NG, Bernard S, Christensen DL, Baass A. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin Biochem 2020;77:20-5. [PMID: 31972148 DOI: 10.1016/j.clinbiochem.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
170 Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645-655. [PMID: 24061205 DOI: 10.1038/nrgastro.2013.182] [Cited by in Crossref: 204] [Cited by in F6Publishing: 186] [Article Influence: 25.5] [Reference Citation Analysis]
171 Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis 2021;9:59-73. [PMID: 33332766 DOI: 10.1002/iid3.391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
172 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
173 Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, Celik A, Bahar K, Karcaaltincaba M. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267:767-775. [PMID: 23382293 DOI: 10.1148/radiol.13121360] [Cited by in Crossref: 209] [Cited by in F6Publishing: 194] [Article Influence: 26.1] [Reference Citation Analysis]
174 Rongey C, Yee HF. From the bedside to the community: Comparative effectiveness, health services, and implementation research. Hepatology 2011;53:673-7. [DOI: 10.1002/hep.24092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
175 Naguib G, Morris N, Yang S, Fryzek N, Haynes-Williams V, Huang WA, Norman-Wheeler J, Rotman Y. Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study. Liver Int 2020;40:590-7. [PMID: 31762148 DOI: 10.1111/liv.14309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
176 Zhang YP, Deng YJ, Tang KR, Chen RS, Liang S, Liang YJ, Han L, Jin L, Liang ZE, Chen YN, Yang QH. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Curr Med Sci 2019;39:37-43. [PMID: 30868489 DOI: 10.1007/s11596-019-1997-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
177 Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(42): 5286-5296 [PMID: 21072891 DOI: 10.3748/wjg.v16.i42.5286] [Cited by in CrossRef: 230] [Cited by in F6Publishing: 209] [Article Influence: 20.9] [Reference Citation Analysis]
178 Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front Med (Lausanne) 2020;7:448. [PMID: 32974366 DOI: 10.3389/fmed.2020.00448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
179 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 16.9] [Reference Citation Analysis]
180 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
181 Bhanji RA, Watt KD. Fatty allograft and cardiovascular outcomes after liver transplantation. Liver Transpl 2017;23:S76-80. [DOI: 10.1002/lt.24843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
182 Bergqvist CJ, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2013;43:247-253. [PMID: 22646061 DOI: 10.1111/j.1445-5994.2012.02848.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
183 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
184 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523. [PMID: 21700865 DOI: 10.1126/science.1204265] [Cited by in Crossref: 1296] [Cited by in F6Publishing: 1266] [Article Influence: 129.6] [Reference Citation Analysis]
185 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
186 Rim MY, Kwon OS, Ha M, Kim JS, Ko KI, Kim DK, Jang PK, Han JY, Park PH, Jung YK, Choi DJ, Kim YS, Kim JH. [Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma]. Korean J Gastroenterol 2014;63:292-8. [PMID: 24870301 DOI: 10.4166/kjg.2014.63.5.292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
187 Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011;91:283-293. [PMID: 20956972 DOI: 10.1038/labinvest.2010.166] [Cited by in Crossref: 137] [Cited by in F6Publishing: 137] [Article Influence: 12.5] [Reference Citation Analysis]
188 Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(45): 6546-6551 [PMID: 23236228 DOI: 10.3748/wjg.v18.i45.6546] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
189 Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res 2013;46:270-7. [PMID: 23532271 DOI: 10.1590/1414-431x20122551] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
190 Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J Hepatol. 2013;59:358-366. [PMID: 23548197 DOI: 10.1016/j.jhep.2013.03.027] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
191 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 821] [Article Influence: 79.2] [Reference Citation Analysis]
192 Lazo M, Bilal U, Perez-Escamilla R. Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep 2015;15:116. [PMID: 26468154 DOI: 10.1007/s11892-015-0674-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
193 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
194 Chen JW, Lin YL, Samuel Wu YH, Wang SY, Chou CH, Chen YC. Ameliorative effects of functional crude-chalaza hydrolysates on the hepatosteatosis development induced by a high-fat diet. Poult Sci 2021;100:101009. [PMID: 33647717 DOI: 10.1016/j.psj.2021.01.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kim MY. [The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:341-7. [PMID: 28637102 DOI: 10.4166/kjg.2017.69.6.341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
196 Goh GBB, Schauer PR, McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World J Gastroenterol 2018; 24(28): 3112-3119 [PMID: 30065557 DOI: 10.3748/wjg.v24.i28.3112] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
197 Krishnan TR, Velusamy P, Mangaiah S, Srinivasan A, Vadivel SK, Murugaiyan U, Periandavan K. Epigallocatechin-3-gallate restores the Bcl-2 expression in liver of young rats challenged with hypercholesterolemia but not in aged rats: an insight into its disparity of efficacy on advancing age. Food Funct 2014;5:916. [DOI: 10.1039/c3fo60345h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
198 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 94] [Article Influence: 15.7] [Reference Citation Analysis]
199 Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G762-G772. [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 16.0] [Reference Citation Analysis]
200 Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015;31:175-183. [PMID: 25774446 DOI: 10.1097/mog.0000000000000175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 12.2] [Reference Citation Analysis]
201 Ramadori P, Weiskirchen R, Trebicka J, Streetz K. Mouse models of metabolic liver injury. Lab Anim 2015;49:47-58. [PMID: 25835738 DOI: 10.1177/0023677215570078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
202 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Zhou YJ, Zhang ZS, Nie YQ, Cao J, Cao CY, Li YY. Association of adiponectin gene variation with progression of nonalcoholic fatty liver disease: A 4-year follow-up survey: NAFLD progression and adiponectin gene. Journal of Digestive Diseases 2015;16:601-9. [DOI: 10.1111/1751-2980.12288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
204 Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci 2013;70:259-76. [DOI: 10.1007/s00018-012-1046-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
205 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878-885. [PMID: 20400681 DOI: 10.1182/blood-2010-02-261891] [Cited by in Crossref: 357] [Cited by in F6Publishing: 294] [Article Influence: 32.5] [Reference Citation Analysis]
206 Trevino MB, Mazur-Hart D, Machida Y, King T, Nadler J, Galkina EV, Poddar A, Dutta S, Imai Y. Liver Perilipin 5 Expression Worsens Hepatosteatosis But Not Insulin Resistance in High Fat-Fed Mice. Mol Endocrinol 2015;29:1414-25. [PMID: 26296152 DOI: 10.1210/me.2015-1069] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
207 Matsuzaka T, Atsumi A, Matsumori R, Nie T, Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K, Shimada M. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology. 2012;56:2199-2208. [PMID: 22753171 DOI: 10.1002/hep.25932] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 13.9] [Reference Citation Analysis]
208 Colombo S, Buonocore M, Del Poggio A, Jamoletti C, Elia S, Mattiello M, Zabbialini D, Del Poggio P. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol. 2012;47:461-469. [PMID: 22223175 DOI: 10.1007/s00535-011-0509-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
209 Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, Boekschoten MV, Müller M, Streetz KL, Trautwein C. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol 2014;61:883-90. [PMID: 24845607 DOI: 10.1016/j.jhep.2014.05.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
210 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
211 Bruno S, Pasquino C, Herrera Sanchez MB, Tapparo M, Figliolini F, Grange C, Chiabotto G, Cedrino M, Deregibus MC, Tetta C, Camussi G. HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis. Mol Ther 2020;28:479-89. [PMID: 31757759 DOI: 10.1016/j.ymthe.2019.10.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
212 Atiemo K, Mazumder NR, Caicedo JC, Ganger D, Gordon E, Montag S, Maddur H, VanWagner LB, Goel S, Kho A, Abecassis M, Zhao L, Ladner D. The Hispanic Paradox in Patients With Liver Cirrhosis: Current Evidence From a Large Regional Retrospective Cohort Study. Transplantation 2019;103:2531-8. [PMID: 30951016 DOI: 10.1097/TP.0000000000002733] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
213 Stine JG, Niccum BA, Zimmet AN, Intagliata N, Caldwell SH, Argo CK, Northup PG. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol 2018;9:140. [PMID: 29511162 DOI: 10.1038/s41424-018-0002-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
214 Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, Vos MB. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6:3187-3201. [PMID: 25111123 DOI: 10.3390/nu6083187] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
215 Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, Cohen JC, Hobbs HH. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61:108-118. [PMID: 24917523 DOI: 10.1002/hep.27242] [Cited by in Crossref: 211] [Cited by in F6Publishing: 197] [Article Influence: 30.1] [Reference Citation Analysis]
216 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 604] [Article Influence: 57.9] [Reference Citation Analysis]
217 谢大伟, 刘翠香, 王炳元, 孙福荣, 李金萍, 丁媛媛, 马力, 王振威, 刘畅. 酒精性脂肪性肝病与非酒精性脂肪性肝病的血液生化学检查特点. 世界华人消化杂志 2010; 18(25): 2654-2659 [DOI: 10.11569/wcjd.v18.i25.2654] [Reference Citation Analysis]
218 Stepanova M, Clement S, Wong R, Saab S, Ahmed A, Younossi ZM. Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. Clin Diabetes 2017;35:79-83. [PMID: 28442821 DOI: 10.2337/cd16-0018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
219 Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med (Lond). 2015;15 Suppl 6:s77-s82. [PMID: 26634687 DOI: 10.7861/clinmedicine.15-6-s77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
220 Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res. 2014;44:E137-E144. [PMID: 24125181 DOI: 10.1111/hepr.12258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
221 Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1470-8. [PMID: 33269500 DOI: 10.1111/jgh.15363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
222 Vujanović M, Brkić-Jovanović N, Ilić D, Drvendžija Z, Srdić-Galić B, Turkulov V, Brkić S, Marić D. Associations of visceral fat thickness and anthropometric measurements with non-alcoholic fatty liver disease development in male patients mono-infected with human immunodeficiency virus. South Afr J HIV Med 2019;20:968. [PMID: 31534788 DOI: 10.4102/sajhivmed.v20i1.968] [Reference Citation Analysis]
223 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 58.0] [Reference Citation Analysis]